23 December 2016
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
10 November 2016
Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.
03 October 2016
Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.
27 July 2016
Russian pharmaceutical company NovaMedica announces strengthening of its team. Elena Ilyina formerly holding one of the key positions in Sun Pharma (Ranbaxy) Russia is appointed as Vice President, Business Development.
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region.
15 December 2015
NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.
29 September 2015
NovaMedica actively involved in RNOF-2015 (Russian National Ophthalmological Forum) that took place in Moscow, September 23, 2015. This is one of the most important educational events in ophthalmology.
22 September 2015
September 17, 2015, Moscow held IBD School (Inflammatory Bowel Disorder School) chaired by the head gastroenterologist of the Moscow Region, Professor Elena Belousova. NovaMedica was the general partner of this educational event that brought together over 100 gastroenterologists from Moscow and other regions of Russia.
16 July 2015
Russian pharmaceutical company NovaMedica takes an active part in the V Baikal Forum on Inflammatory Bowel Diseases (IBD), which befalls from 16 to 18 of July in Irkutsk. Participating in this event NovaMedica opens a series of scientific and practical programs for the professional community of gastroenterologists.
03 July 2020
03 July 2020
02 July 2020
02 July 2020